Synthetic Chemical Biology Core

项目摘要 – 核心 C 合成化学生物学核心（SCB）成立于2016年7月，由合成化学生物学中心合并而成。 疾病途径分子分析 (CMADP) 分子探针核心与新建立的化学 传染病生物学（CBID）药物化学核心。 SCB 的综合能力将满足 两个 COBRE 中心的具体目标。 SCB 在第三阶段的任务是提供 CMADP 附属的服务 初级教师以及堪萨斯州的其他研究人员使用新颖的分子探针 用于体外或体内阐明特定途径的药理学工具。 SCB还将致力于 在第三阶段之后实现自我可持续发展。核心将提供小分子的专家设计和合成 和肽分子探针，重点是荧光和其他亲和标记的生成 分子。 SCB 将与 CMADP 资助的其他核心设施（包括基因组）协同运作 测序核心，用于识别影响体内探针功能的基因，以及 KU 纳米加工设施， 开发成像和化学分析设备。这种集成旨在使教师能够使用 研究生物学问题的化学生物学方法。 SCB 在第三阶段将解决的具体目标是： (1) 提供有利的小分子 COBRE 调查人员和其他客户的利益； (2) 提供常规和专用肽的合成 给调查人员； (3) 提供管理上述所需的外展、行政和财政支持 COBRE 项目背景下的活动以及为更大的堪萨斯研究界提供服务 (4) 继续发展足够数量的核心实验室用户，使该设施成为一个自我维持的、完整的 堪萨斯州生物医学研究基础设施的一部分。

PROJECT SUMMARY – CORE C The Synthetic Chemical Biology Core (SCB) was established in July 2016 from the merger of the Center for Molecular Analysis of Disease Pathways (CMADP) Molecular Probes Core with the newly established Chemical Biology of Infectious Disease (CBID) Medicinal Chemistry Core. The synthetic capabilities of the SCB will fulfill the specific aims of both COBRE centers. The mission for the SCB in Phase 3 is to provide CMADP-affiliated junior faculty, as well as other investigators in the state of Kansas, with novel molecular probes as pharmacological tools for in vitro or in vivo elucidation of particular pathways. The SCB will also work towards achieving self-sustainability beyond Phase 3. The Core will offer expert design and synthesis of small molecule and peptide molecular probes, with an emphasis on the generation of fluorescent and other affinity tagged molecules. The SCB will function synergistically with other CMADP-funded Core facilities, including the Genome Sequencing Core, to identify genes that impact functions of probes in vivo, and the KU Nanofabrication Facility, to develop devices for imaging and chemical analysis. This integration is designed to empower faculty to use chemical biology approaches to investigate biological problems. The specific aims that will be addressed by the SCB in Phase 3 are: (1) Provide enabling small molecules of interest to COBRE investigators and other clients; (2) Provide synthesis of conventional and specialized peptides to investigators; (3) Provide outreach, administrative, and fiscal support necessary to manage the above activities both in the context of COBRE projects and to offer services to the larger Kansas research community (4) To continue developing a critical mass of core lab users so that the facility becomes a self-sustaining, integral part of the biomedical research infrastructure in the state of Kansas.